1
|
Massy N, Atzenhoffer M, Boulay C, Pecquet PE, Ledys F, Cracowski JL, Masmoudi K, Lepelley M, Gras-Champel V. [COVID-19 and adenovirus vaccines: French experience of enhanced pharmacovigilance]. Therapie 2023; 78:489-498. [PMID: 36759287 PMCID: PMC9862661 DOI: 10.1016/j.therap.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Accepted: 01/16/2023] [Indexed: 01/22/2023]
Abstract
As part of the COVID-19 vaccination campaign, the National Agency for the Safety of Medicines and Health Products and all 31 regional pharmacovigilance centers were mobilized in an exceptional reinforced vaccine pharmacovigilance surveillance system. Concerning adenovirus vaccines, Vaxzévria® and Jcovden®, this national system, based on the daily analysis of notified cases of adverse events, has allowed the early identification of safety signals, some of which have been validated, others still under analysis, common to mRNA vaccines or more specific of adenovirus vaccines such as Vaccine Induced Immune Thrombocytopenia. Complementing european and international actions, this follow-up has contributed to a better definition of the safety profile of these vaccines and has led to redefine the vaccine strategy in our country. Although today these two vaccines have no longer place in the national vaccine strategy, they are still used in other countries, where the experience acquired could be useful and will contribute to fuel the reflection on future therapies involving viral vectors.
Collapse
Affiliation(s)
- Nathalie Massy
- Centre régional de pharmacovigilance, service de pharmacologie, CHU Rouen, 76031 Rouen, France
| | - Marina Atzenhoffer
- Centre régional de pharmacovigilance, service hospitalo-universitaire de pharmacologie et toxicologie, hospices civils de Lyon, 69424 Lyon, France
| | - Charlène Boulay
- Centre régional de pharmacovigilance, service de pharmacologie, CHU Rouen, 76031 Rouen, France
| | - Pauline-Eva Pecquet
- Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, 80054 Amiens, France
| | - Fanny Ledys
- Centre régional de pharmacovigilance, service hospitalo-universitaire de pharmacologie et toxicologie, hospices civils de Lyon, 69424 Lyon, France
| | - Jean-Luc Cracowski
- Centre régional de pharmacovigilance, service de pharmacologie, CHU Grenoble, 38043 Grenoble cedex 09, France
| | - Kamel Masmoudi
- Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, 80054 Amiens, France
| | - Marion Lepelley
- Centre régional de pharmacovigilance, service de pharmacologie, CHU Grenoble, 38043 Grenoble cedex 09, France
| | - Valérie Gras-Champel
- Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, 80054 Amiens, France.
| |
Collapse
|
2
|
Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S. Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers (Basel) 2021; 13:5999. [PMID: 34885109 PMCID: PMC8656936 DOI: 10.3390/cancers13235999] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/16/2021] [Accepted: 11/19/2021] [Indexed: 12/12/2022] Open
Abstract
Despite a few cases of long-responder patients, immunotherapy with anti-PD-(L)1 has so far proved rather disappointing in monotherapy in metastatic breast cancer, prompting the use of synergistic therapeutic combinations incorporating immunotherapy by immune-checkpoint inhibitors. In addition, a better understanding of both the mechanisms of sensitivity and resistance to immunotherapy, as well as the immunological effects of the usual treatments for breast cancer, make it possible to rationally consider this type of therapeutic combination. For several years, certain treatments, commonly used to treat patients with breast cancer, have shown that in addition to their direct cytotoxic effects, they may have an impact on the tumor immune microenvironment, by increasing the antigenicity and/or immunogenicity of a "cold" tumor, targeting the immunosuppressive microenvironment or counteracting the immune-exclusion profile. This review focuses on preclinical immunologic synergic mechanisms of various standard therapeutic approaches with anti-PD-(L)1, and discusses the potential clinical use of anti-PD-1/L1 combinations in metastatic or early breast cancer.
Collapse
Affiliation(s)
- Fanny Ledys
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Center, 21000 Dijon, France; (F.L.); (L.K.); (L.G.); (E.L.)
- School of Medicine and Pharmacy, University of Burgundy Franche-Comté, 21000 Dijon, France
- UMR INSERM 1231, Lipides Nutrition Cancer, 21000 Dijon, France
| | - Laura Kalfeist
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Center, 21000 Dijon, France; (F.L.); (L.K.); (L.G.); (E.L.)
- School of Medicine and Pharmacy, University of Burgundy Franche-Comté, 21000 Dijon, France
- UMR INSERM 1231, Lipides Nutrition Cancer, 21000 Dijon, France
| | - Loick Galland
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Center, 21000 Dijon, France; (F.L.); (L.K.); (L.G.); (E.L.)
- Department of Medical Oncology, Georges-François Leclerc Center, 21000 Dijon, France
| | - Emeric Limagne
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Center, 21000 Dijon, France; (F.L.); (L.K.); (L.G.); (E.L.)
- School of Medicine and Pharmacy, University of Burgundy Franche-Comté, 21000 Dijon, France
- UMR INSERM 1231, Lipides Nutrition Cancer, 21000 Dijon, France
| | - Sylvain Ladoire
- Platform of Transfer in Cancer Biology, Georges-François Leclerc Center, 21000 Dijon, France; (F.L.); (L.K.); (L.G.); (E.L.)
- School of Medicine and Pharmacy, University of Burgundy Franche-Comté, 21000 Dijon, France
- UMR INSERM 1231, Lipides Nutrition Cancer, 21000 Dijon, France
- Department of Medical Oncology, Georges-François Leclerc Center, 21000 Dijon, France
| |
Collapse
|
3
|
Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F. Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer 2019; 121:283. [PMID: 31235866 PMCID: PMC6738095 DOI: 10.1038/s41416-019-0512-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Jean-David Fumet
- Department of Medical Oncology, Center GF Leclerc, Dijon, France.,Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France.,University of Burgundy-Franche Comté, Dijon, France
| | - Corentin Richard
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France.,University of Burgundy-Franche Comté, Dijon, France
| | - Fanny Ledys
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France.,University of Burgundy-Franche Comté, Dijon, France
| | - Quentin Klopfenstein
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - Philippe Joubert
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada
| | - Bertrand Routy
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.,Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - Caroline Truntzer
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - Andréanne Gagné
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada
| | - Marc-André Hamel
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada
| | - Camila Figueiredo Guimaraes
- Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada
| | - Bruno Coudert
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | | | - Laure Favier
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Aurélie Lagrange
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Sylvain Ladoire
- Department of Medical Oncology, Center GF Leclerc, Dijon, France.,University of Burgundy-Franche Comté, Dijon, France
| | - Pierre Saintigny
- Department of Medical Oncology, Center Leon Berard, Lyon, France
| | | | - Maurice Perol
- Department of Medical Oncology, Center Leon Berard, Lyon, France
| | - Pascal Foucher
- Department of Thoracic Oncology, Dijon University Hospital, Dijon, France
| | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France.,Hospital-Integrated Biobank (BB-0033-00025), FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France
| | - Marius Ilie
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France.,Hospital-Integrated Biobank (BB-0033-00025), FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France
| | - Sandy Chevrier
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - Romain Boidot
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - Valentin Derangere
- Research Platform in Biological Oncology, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - François Ghiringhelli
- Department of Medical Oncology, Center GF Leclerc, Dijon, France. .,Research Platform in Biological Oncology, Dijon, France. .,GIMI Genetic and Immunology Medical Institute, Dijon, France. .,University of Burgundy-Franche Comté, Dijon, France. .,INSERM UMR1231, Dijon, France.
| |
Collapse
|
4
|
Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C. Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale. Adv Ther 2019; 36:1480-1484. [PMID: 30980281 DOI: 10.1007/s12325-019-00949-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Indexed: 11/26/2022]
Abstract
KRAS (Kirsten rat sarcoma viral oncogene) or BRAF (v-raf murine sarcoma viral oncogene homolog B1) constitutive activation leads to anti-EGFR (epidermal growth factor receptor) therapy resistance of metastatic colorectal cancer patients. In this article we investigate the effects of anti-MEK (mitogen-activated protein kinase) antibody (trametinib) combined with anti-EGFR (cetuximab) on colon cancer cell lines with different RAS statuses. Even though cetuximab has no effect on RAS cell viability and ERK (extracellular-signal-regulated kinase) phosphorylation (one of the last kinases of the EGFR pathway), trametinib can induce cell death and inhibit the activation of ERK alone or in combination with cetuximab. In a more pathologic context, we observed that KRAS colon cancer patient biopsies treated ex vivo with trametinib and cetuximab also present less ERK phosphorylation. Finally, nine ovarian, endometrial and colon cancer patients with different KRAS statuses were treated with anti-EGFR/anti-MEK combination off label after molecular tumor board decision. KRAS exon 2 patients have significantly longer PFS (progression-free survival) than with previous lines of treatments. We believe that such observations provide a rationale for designing a clinical trial to test this association in RAS exon 2 mutated cancers.
Collapse
Affiliation(s)
- Fanny Ledys
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
- University of Bourgogne Franche-Comté, 21000, Dijon, France
| | - Valentin Derangère
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
- University of Bourgogne Franche-Comté, 21000, Dijon, France
| | - Manon Réda
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Jean-Florian Guion
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Romily Milliex
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Valérie Roux
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Emeric Limagne
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Laurent Arnould
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
- Department of Pathology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - Leila Bengrine
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000, Dijon, France
| | - François Ghiringhelli
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France
- University of Bourgogne Franche-Comté, 21000, Dijon, France
- Department of Medical Oncology, Centre Georges-François Leclerc, 21000, Dijon, France
- INSERM LNC-UMR1231, 21000, Dijon, France
| | - Cédric Rébé
- Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, 21000, Dijon, France.
- University of Bourgogne Franche-Comté, 21000, Dijon, France.
- INSERM LNC-UMR1231, 21000, Dijon, France.
| |
Collapse
|
5
|
Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V. RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer. J Immunother Cancer 2018; 6:123. [PMID: 30454021 PMCID: PMC6245855 DOI: 10.1186/s40425-018-0438-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Accepted: 10/31/2018] [Indexed: 12/20/2022] Open
Abstract
Background T lymphocytes and HLA expression on tumor cell both influence prognostic of localized colorectal cancer, but their role following chemotherapy in patients with liver metastatic colorectal cancer (mCRC) was not addressed. Methods One hundred fourteen patients treated in curative intend of liver mCRC were included in this retrospective study. Patients were either untreated or treated with neoadjuvant therapy containing an anti-EGFR, bevacizumab or oxaliplatin. Immune densities were quantified in the tumor core and in invasive margin of metastases, using Qupath software or a pathologist’s quantification. CD8, NKp46, Foxp3, CD163, HLA, PD-L1 were analyzed and were correlated with progression free survival (PFS) and overall survival (OS) using multivariable Cox proportional hazards models. Results In the whole cohort only a high CD8+ cells infiltrate, a high HLA-I expression and wild-type RAS/RAF status were associated with a better overall survival in both univariate and multivariate model. Moreover, CD8+ cells immune infiltrate at invasive margin combined to HLA expression in cancer cell could increase patient’s outcome prediction. RAS status but not immune cell infiltrate was associated with HLA expression on tumor cells. In comparison to untreated patients, neoadjuvant chemotherapy induced CD8+ cells recruitment and increased PD-L1 staining in immune infiltrates only for WT RAS patients. In this context, anti-EGFR and oxaliplatin based chemotherapy are the most powerful to induce CD8+ cells mobilization within the metastatic site. Conclusions While CD8 infiltrate and HLA expression appear to be prognostic for mCRC, CD8 and PD-L1 infiltrate are enhanced by neoadjuvant chemotherapy in mCRC under RAS status dependence. Electronic supplementary material The online version of this article (10.1186/s40425-018-0438-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fanny Ledys
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France.,Université de Bourgogne-Franche comté, Faculté des Sciences de Santé, Dijon, France
| | - Quentin Klopfenstein
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France
| | - Caroline Truntzer
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France
| | - Laurent Arnould
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France.,Department of Pathology, Centre Georges-François Leclerc, Dijon, France
| | - Julie Vincent
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Leila Bengrine
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Romain Remark
- Innate Pharma, 117 Avenue de Luminy, Marseille, France
| | - Romain Boidot
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France.,GIMI Genetic and Immunology Medical Institute, Dijon, France
| | - Sylvain Ladoire
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France.,Université de Bourgogne-Franche comté, Faculté des Sciences de Santé, Dijon, France.,Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.,INSERM UMR1231, Dijon, France
| | - Francois Ghiringhelli
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France. .,Université de Bourgogne-Franche comté, Faculté des Sciences de Santé, Dijon, France. .,GIMI Genetic and Immunology Medical Institute, Dijon, France. .,Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. .,INSERM UMR1231, Dijon, France.
| | - Valentin Derangere
- Cancer Biology Research Platform, Centre Georges-François Leclerc, Dijon, France. .,Université de Bourgogne-Franche comté, Faculté des Sciences de Santé, Dijon, France. .,GIMI Genetic and Immunology Medical Institute, Dijon, France.
| |
Collapse
|
6
|
Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. Clin Cancer Res 2018; 25:957-966. [PMID: 30154227 DOI: 10.1158/1078-0432.ccr-18-1940] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 07/31/2018] [Accepted: 08/22/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Immune checkpoint inhibitors revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies. PD-L1 assessment and tumor mutational burden (TMB) are available tools to optimize use of checkpoint inhibitors but novel tools are needed. Exome sequencing could generate many variables but their role in identifying predictors of response is unknown. EXPERIMENTAL DESIGN We performed somatic and constitutional exome analyses for 77 patients with NSCLC treated with nivolumab. We studied: one-tumor-related characteristics: aneuploidy, CNA clonality, mutational signatures, TMB, mutations in WNT, AKT, MAPK, and DNA repair pathways, and two-immunologic characteristics: number of intratumoral TCR clones, HLA types, and number of neoantigens; and six clinical parameters. RESULTS A high TMB per Mb, a high number of neoantigens, mutational signatures 1A and 1B, mutations in DNA repair pathways, and a low number of TCR clones are associated with greater PFS. Using a LASSO method, we established an exome-based model with nine exome parameters that could discriminate patients with good or poor PFS (P < 0.0001) and overall survival (P = 0.002). This model shows better ability to predict outcomes compared with a PD-L1 clinical model with or without TMB. It was externally validated on two cohorts of patients with NSCLC treated with pembrolizumab or with nivolumab and ipilimumab as well as in urothelial tumors treated with atezolizumab. CONCLUSIONS Altogether, these data provide a validated biomarker that predicts the efficacy of nivolumab or pembrolizumab in patients with NSCLC. Our biomarker seems to be superior to PD-L1 labeling and TMB models.
Collapse
Affiliation(s)
- Corentin Richard
- Platform of Transfer in Cancer Biology, France.,University of Burgundy Franche-Comté, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Jean-David Fumet
- Platform of Transfer in Cancer Biology, France.,University of Burgundy Franche-Comté, France.,Genetic and Immunology Medical Institute, Dijon, France.,Department of Medical Oncology, Georges-Francois LECLERC Cancer Center - UNICANCER, Dijon, France
| | - Sandy Chevrier
- Platform of Transfer in Cancer Biology, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Valentin Derangère
- Platform of Transfer in Cancer Biology, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Fanny Ledys
- Platform of Transfer in Cancer Biology, France.,University of Burgundy Franche-Comté, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Aurélie Lagrange
- Department of Medical Oncology, Georges-Francois LECLERC Cancer Center - UNICANCER, Dijon, France
| | - Laure Favier
- Department of Medical Oncology, Georges-Francois LECLERC Cancer Center - UNICANCER, Dijon, France
| | - Bruno Coudert
- Department of Medical Oncology, Georges-Francois LECLERC Cancer Center - UNICANCER, Dijon, France
| | - Laurent Arnould
- Platform of Transfer in Cancer Biology, France.,Genetic and Immunology Medical Institute, Dijon, France.,Department of Tumor Biology and Pathology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France
| | - Caroline Truntzer
- Platform of Transfer in Cancer Biology, France.,Genetic and Immunology Medical Institute, Dijon, France
| | - Romain Boidot
- Platform of Transfer in Cancer Biology, France.,University of Burgundy Franche-Comté, France.,Genetic and Immunology Medical Institute, Dijon, France.,Department of Tumor Biology and Pathology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France.,INSERM U1231, Dijon, France
| | - François Ghiringhelli
- Platform of Transfer in Cancer Biology, France. .,University of Burgundy Franche-Comté, France.,Genetic and Immunology Medical Institute, Dijon, France.,Department of Medical Oncology, Georges-Francois LECLERC Cancer Center - UNICANCER, Dijon, France.,Department of Tumor Biology and Pathology, Georges François Leclerc Cancer Center - UNICANCER, Dijon, France.,INSERM U1231, Dijon, France
| |
Collapse
|
7
|
Richard C, Fumet JD, Chevrier S, Derangere V, Ledys F, Lagrange A, Favier L, Coudert BP, Arnould L, Truntzer C, Boidot R, Ghiringhelli F. Exome analysis to reveal genomic markers associated with better efficacy of nivolumab in lung cancer patients. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.9044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Corentin Richard
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Jean-David Fumet
- Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
| | - Sandy Chevrier
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Valentin Derangere
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Fanny Ledys
- Research Platform in Biological Oncology, Dijon, France
| | - Aurelie Lagrange
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Laure Favier
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Bruno P. Coudert
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | | | - Caroline Truntzer
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Romain Boidot
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | | |
Collapse
|
8
|
Fumet JD, Richard C, Ledys F, Klopfenstein Q, Truntzer C, Coudert BP, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F. CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.3021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jean-David Fumet
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Corentin Richard
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Fanny Ledys
- Research Platform in Biological Oncology, Dijon, France
| | | | - Caroline Truntzer
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Bruno P. Coudert
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | | | - Laure Favier
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Aurelie Lagrange
- Department of Medical Oncology, Center GF Leclerc, Dijon, France
| | - Sylvain Ladoire
- Department of Medical Oncology, Center GF Leclerc, Dijon Cedex, FR
| | - Pierre Saintigny
- INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Université de Lyon, Centre Léon Bérard, Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon, Lyon, France
| | - Sandra Ortiz-Cuaran
- INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Université de Lyon, Centre Léon Bérard, Université Lyon 1, ISPB, Faculté de Pharmacie de Lyon, Lyon, France
| | - Maurice Perol
- Department of Thoracic Oncology, Centre Léon Bérard, Lyon, France
| | | | - Paul Hofman
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d'Azur, Nice, France
| | - Marius Ilie
- Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, University Côte d'Azur, Nice, France
| | - Sandy Chevrier
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Romain Boidot
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | - Valentin Derangere
- Research Platform in Biological Oncology, Center GF Leclerc, Dijon, France
| | | |
Collapse
|